The Effect of Parathyroid Hormone (1-84) Treatment on Serum Bone Morphogenetic Protein 4 and Vascular Endothelial Growth Factor in Postmenopausal Women with Established Osteoporosis

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2017 Feb 27

PMID 28238166

Citations 5

Authors

J Pepe

C Cipriani

F P Cantatore

A Fabbri

E Pola

V Vinicola

O Raimo

F Biamonte

R Pascone

C Ferrara

S Minisola

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the effect of 18 months' parathyroid hormone 1-84 (PTH 1-84) treatment on serum levels of bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF), in postmenopausal women with established osteoporosis.

Methods: Thirty-seven postmenopausal women with osteoporosis (mean age 72.9 ± 8.1 years old) and 23 healthy controls (mean age 68.9 ± 9.9 years old) were enrolled. Patients were treated with daily subcutaneous injections of PTH (1-84) 100 mcg for 18 months, plus calcium 1 gr and vitamin D 800 IU per os daily. Blood samples were taken every 6 months during the study.

Results: At baseline, there were no differences considering anthropometric parameters, co-morbidities, current medications used between patients and controls. Mean serum VEGF levels were significantly higher in osteoporotic patients compared to controls (436.7 ± 259.7 vs. 260.3 ± 184.3 pg/ml, p = 0.006), while there were no differences in mean serum values of BMP4 (5.3 ± 1.7 vs. 5.7 ± 1.6 pg/ml, p = 0.40). Serum VEGF levels increased by approximately 20% after 12 months of PTH (1-84) treatment compared to baseline (p = 0.03) and by 22% after 18 months (p = 0.01). A significant increase of 10% in mean serum BMP4 levels was observed after 18 months of PTH (1-84) treatment compared to baseline (p = 0.02). In the control group we found no differences after 18 months compared to baseline in BMP4 (5.7 ± 1.6 vs. 6.0 ± 1.5 pg/ml, p = 0.53) and VEGF (260.3 ± 184.3 vs. 257.4 ± 107.1 pg/ml, p = 0.94).

Conclusions: PTH (1-84) treatment increased serum levels of VEGF and BMP4 in postmenopausal women with severe osteoporosis.

Citing Articles

Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D.

Bellone F, Catalano A, Sottile A, Gaudio A, Loddo S, Corica F Front Med (Lausanne). 2021; 8:748438.

PMID: 34869440 PMC: 8636794. DOI: 10.3389/fmed.2021.748438.

Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.

Anastasilakis A, Polyzos S, Makras P, Rauner M, Sonnleitner L, Hawa G J Musculoskelet Neuronal Interact. 2019; 19(3):253-257.

PMID: 31475931 PMC: 6737552.

State of the art in osteoporosis risk assessment and treatment.

Liu J, Curtis E, Cooper C, Harvey N J Endocrinol Invest. 2019; 42(10):1149-1164.

PMID: 30980341 PMC: 6751157. DOI: 10.1007/s40618-019-01041-6.

Retinal micro-vascular and aortic macro-vascular changes in postmenopausal women with primary hyperparathyroidism.

Pepe J, Cipriani C, Tedeschi M, Curione M, Parravano M, Varano M Sci Rep. 2018; 8(1):16521.

PMID: 30410012 PMC: 6224616. DOI: 10.1038/s41598-018-35017-y.

The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study.

Cipriani C, Pepe J, Bertoldo F, Bianchi G, Cantatore F, Corrado A J Endocrinol Invest. 2017; 41(4):431-438.

PMID: 28956296 DOI: 10.1007/s40618-017-0761-4.

References

Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S . The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab. 2011; 96(5):1555-9. DOI: 10.1210/jc.2010-2552. View

Brunner S, Theiss H, Murr A, Negele T, Franz W . Primary hyperparathyroidism is associated with increased circulating bone marrow-derived progenitor cells. Am J Physiol Endocrinol Metab. 2007; 293(6):E1670-5. DOI: 10.1152/ajpendo.00287.2007. View

Biver E, Hardouin P, Caverzasio J . The "bone morphogenic proteins" pathways in bone and joint diseases: translational perspectives from physiopathology to therapeutic targets. Cytokine Growth Factor Rev. 2012; 24(1):69-81. DOI: 10.1016/j.cytogfr.2012.06.003. View

Peng H, Wright V, Usas A, Gearhart B, Shen H, Cummins J . Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest. 2002; 110(6):751-9. PMC: 151123. DOI: 10.1172/JCI15153. View

Cusano N, Rubin M, Zhang C, Anderson L, Levy E, Costa A . Parathyroid hormone 1-84 alters circulating vascular endothelial growth factor levels in hypoparathyroidism. J Clin Endocrinol Metab. 2014; 99(10):E2025-8. PMC: 4184068. DOI: 10.1210/jc.2014-1500. View

Christodoulakos G, Lambrinoudaki I, Panoulis C, Papadias C, Sarandakou A, Liakakos T . Effect of hormone therapy, tibolone and raloxifene on circulating vascular endothelial growth factor in Greek postmenopausal women. Eur J Endocrinol. 2004; 151(2):187-92. DOI: 10.1530/eje.0.1510187. View

Suzawa M, Takeuchi Y, Fukumoto S, Kato S, Ueno N, Miyazono K . Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro. Endocrinology. 1999; 140(5):2125-33. DOI: 10.1210/endo.140.5.6704. View

Street J, Lenehan B . Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism. J Orthop Surg Res. 2009; 4:19. PMC: 2701940. DOI: 10.1186/1749-799X-4-19. View

Pufe T, Scholz-Ahrens K, Franke A, Petersen W, Mentlein R, Varoga D . The role of vascular endothelial growth factor in glucocorticoid-induced bone loss: evaluation in a minipig model. Bone. 2003; 33(6):869-76. DOI: 10.1016/j.bone.2003.08.002. View

10.

Piemonte S, Romagnoli E, Bratengeier C, Woloszczuk W, Tancredi A, Pepe J . Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone. J Endocrinol Invest. 2012; 35(9):866-8. DOI: 10.3275/8522. View

11.

Lewiecki E, Binkley N . What we don't know about osteoporosis. J Endocrinol Invest. 2016; 39(5):491-3. DOI: 10.1007/s40618-016-0442-8. View

12.

Prisby R, Menezes T, Campbell J . Vasodilation to PTH (1-84) in bone arteries is dependent upon the vascular endothelium and is mediated partially via VEGF signaling. Bone. 2013; 54(1):68-75. DOI: 10.1016/j.bone.2013.01.028. View

13.

Paglia F, Dionisi S, De Geronimo S, Rosso R, Romagnoli E, Raejntroph N . Biomarkers of bone turnover after a short period of steroid therapy in elderly men. Clin Chem. 2001; 47(7):1314-6. View

14.

Senel K, Baykal T, Seferoglu B, Altas E, Baygutalp F, Ugur M . Circulating vascular endothelial growth factor concentrations in patients with postmenopausal osteoporosis. Arch Med Sci. 2013; 9(4):709-12. PMC: 3776175. DOI: 10.5114/aoms.2013.36896. View

15.

Russo S, Carlucci L, Cipriani C, Ragno A, Piemonte S, Del Fiacco R . Metabolic changes following 500 μg monthly administration of calcidiol: a study in normal females. Calcif Tissue Int. 2011; 89(3):252-7. DOI: 10.1007/s00223-011-9513-1. View

16.

Kamiya N, Kobayashi T, Mochida Y, Yu P, Yamauchi M, Kronenberg H . Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res. 2009; 25(2):200-10. PMC: 3153381. DOI: 10.1359/jbmr.090806. View

17.

Cebi H, Aksahin E, Yuksel H, Celebi L, Aktekin C, Hapa O . Plasma vascular endothelial growth factor levels are similar in subjects with and without osteoporosis. Eklem Hastalik Cerrahisi. 2010; 21(2):91-7. View

18.

Lasco A, Catalano A, Morabito N, Gaudio A, Basile G, Trifiletti A . Adrenal effects of teriparatide in the treatment of severe postmenopausal osteoporosis. Osteoporos Int. 2010; 22(1):299-303. DOI: 10.1007/s00198-010-1222-5. View

19.

Luppen C, Chandler R, Noh T, Mortlock D, Frenkel B . BMP-2 vs. BMP-4 expression and activity in glucocorticoid-arrested MC3T3-E1 osteoblasts: Smad signaling, not alkaline phosphatase activity, predicts rescue of mineralization. Growth Factors. 2008; 26(4):226-37. PMC: 3760374. DOI: 10.1080/08977190802277880. View

20.

Dincel V, Sepici-Dincel A . The importance and the differences of bone morphogenetic proteins for osteoporotic hip fractures. Acta Orthop Belg. 2014; 80(2):216-21. View